

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Website:- www.medicaps.com

MCL/SE/2023-2024

Date: 11th August, 2023

Online filing at: www.listing.bseindia.com

To,

The General Manager

DCS-CRD

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street Fort, Mumbai – 400001 (M.H.)

Subject: Submission of the Standalone and Consolidated un-audited Financial Results for the Quarter ended on 30th June, 2023 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reference: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

This is in continuation of our letter no. MCL/BM/SE/2023-2024 dated 04th August, 2023 regarding intimation of Board of Directors meeting for consideration and approval of Standalone as well as Consolidated un-audited Financial Results for the Quarter ended on 30th June, 2023.

We are pleased to inform that, in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Board of Directors in their meetings held on 11th August, 2023 has considered and approved the following businesses:

- (a) Un-audited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2023; and
- (b) Limited Review Report by the Statutory Auditors of the Company for the un-audited Standalone and Consolidated quarter ended on 30th June, 2023.

Further we are also in process of filing the aforesaid un-audited financial results in the XBRL format within 24 hours from the conclusion of Board Meeting.

The aforesaid results shall also be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange i.e., at www.bseindia.com. Further, the extract of aforesaid results shall also be published in Hindi (vernacular) and widely circulated English Newspaper.

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Website:- www.medicaps.com

You are requested to please take on record the aforesaid un-audited Financial Results along with Limited review Report for your records and reference.

Thanking You,

FOR MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Enclosed: Un-audited Standalone and Consolidated Financial Results along With Limited Review Report for the quarter ended 30th June, 2023.

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter ended 30th June 2023 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 11.08.2023


Place: Indore

UDIN: 23429040BGXBEV3382

For, Rawka & Associates

(Chartered Accountants)

FRN 021606C



A handwritten signature in black ink, appearing to read "Venus Rawka".

Venus Rawka
(Partner)

M. No. 429040

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, cprawka@gmail.com


LIMITED REVIEW REPORT

Independent Auditor's Review Report On Consolidated Unaudited Quarterly Financial Results of Medi-Caps Limited (the Parent Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter ended June 30, 2023, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the SEBI Listing Regulations"), including relevant circular issued by the SEBI time to time.
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would



become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly-owned subsidiary **Medgel Private Limited**.

CONCLUSION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also has been reviewed by us and certified by the management, whose interim consolidated financial results reflect a total income of Rs.644.45 Lakhs, total net loss after tax of Rs. (111.45) Lakhs and total comprehensive income of Rs. (1.63) Lakhs for the quarter ended June 30, 2023 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of the above matter.

Date: 11.08.2023

Place: Indore

UDIN: 23429040BGXBEW3949

For, Rawka & Associates

(Chartered Accountants)

FRN 021606C



Venus Rawka
(Partner)

M. No. 429040

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

Amount in Lacs except EPS

S.N.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30th, 2023	March 31st, 2023	June 30th 2022	March 31st, 2023	June 30th, 2023	March 31st, 2023	June 30th 2022	March 31st, 2023
	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
I	Revenue from Operation								
	(a) Net sales	0.00	0.00	0.00	0.00	623.64	1018.37	1217.25	4857.75
	(b) Other operating income	1.77	6.22	1.36	10.14	14.06	38.54	21.80	79.35
	Revenue from Operation	1.77	6.22	1.36	10.14	637.70	1056.92	1239.05	4937.10
II	Other Income	0.80	2.59	1.26	64.46	6.75	23.83	29.72	160.32
III	Total income (I+II)	2.57	8.81	2.62	74.60	644.45	1080.74	1268.77	5097.42
IV	Expenses								
	a) Cost of material consumed	0.00	0.00	0.00	0.00	270.04	484.82	543.77	2205.25
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	23.73	-111.24	69.57	85.21
	d) Employee benefits expense	6.10	5.71	5.41	23.27	179.33	221.52	167.62	768.92
	e) Finance costs	0.00	0.00	0.00	0.00	0.00	0.01	0.12	0.16
	f) Depreciation and amortisation expense	4.00	2.31	2.31	9.23	45.27	22.06	50.25	174.32
	g) Power Cost	0.06	0.02	0.00	0.21	37.91	61.53	44.93	216.22
	h) Freight Exp.	0.00	0.00	0.00	0.00	13.90	110.53	168.57	505.30
	i) Other expenses	30.63	3.78	6.58	16.32	185.72	212.08	160.76	649.97
	Total Expenses (IV)	40.79	11.82	14.30	49.03	755.90	1001.31	1205.59	4605.35
V	Profit / (Loss) before exceptional item & tax (III-IV)	-38.22	-3.01	-11.68	25.57	-111.45	79.43	63.18	492.07
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	-38.22	-3.01	-11.68	25.57	-111.45	79.43	63.18	492.07
VIII	Tax expense								
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	42.00	0.00	122.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00	0.00	0.00	183.58
	3) Deferred Tax	0.00	-0.14	0.00	-0.14	0.00	-0.14	0.00	-0.14
	Total Tax Expenses	0.00	-0.14	0.00	-0.14	0.00	41.86	0.00	305.44
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	-38.22	-2.87	-11.68	25.71	-111.45	37.58	63.18	186.63
XI	Profit/(loss) from discontinued operations	0.00	-1.36	-4.31	-11.07	0.00	-1.36	-4.31	-11.07
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.00	-1.36	-4.31	-11.07	0.00	-1.36	-4.31	-11.07

XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XV	Profit/(loss) for the period (X+XIII)	-38.22	-4.23	-15.99	14.64	-111.45	36.22	58.87	175.56
XVI	Other comprehensive income								
	(a) (i) items that will not be reclassified to statement of profit & loss	30.22	-1.38	-24.48	-32.70	109.82	24.17	-47.30	55.95
	(ii) Income tax on items that will not be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	30.22	-1.38	-24.48	-32.70	109.82	24.17	-47.30	55.95
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-8.00	-5.61	-40.47	-18.06	-1.63	60.39	11.57	231.51
XVIII	Profit or Loss Attributable to								
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	-111.45	36.22	58.87	175.56
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to								
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	-1.63	60.39	11.57	231.51
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	4863.75	0.00	0.00	0.00	10610.14
XXII	Earnings per equity share (for continuing operation)								
	a) Basic (Rs.)	-0.31	-0.02	-0.09	0.21	-0.89	0.30	0.51	1.50
	b) Diluted (Rs.)	-0.31	-0.02	-0.09	0.21	-0.89	0.30	0.51	1.50
	Earnings per equity share (for discontinued operation)								
	a) Basic (Rs.)	0.00	-0.01	-0.03	-0.09	0.00	-0.01	-0.03	-0.09
	b) Diluted (Rs.)	0.00	-0.01	-0.03	-0.09	0.00	-0.01	-0.03	-0.09
	Earnings per equity share (for discontinued and continuing operation)								
	a) Basic (Rs.)	-0.31	-0.03	-0.12	0.12	-0.89	0.29	0.48	1.41
	b) Diluted (Rs.)	-0.31	-0.03	-0.12	0.12	-0.89	0.29	0.48	1.41

DATE: 11.08.2023

PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435					
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70400MP1983PLC002231					
Consolidated Segmentwise Revenue, Results and Capital Employed for Quarter ended 30th June, 2023					
(Amount in Lakhs)					
S.No.	Segment Revenue	Quarter Ended			Year Ended
		June 30th, 2023	March 31st, 2023	June 30th 2022	March 31st 2023
		Unaudited	Audited	Unaudited	Audited
1	Segment Revenue				
	Pharma Division	641.89	1071.93	1266.16	5022.83
	Real Estate Division	2.57	8.81	2.62	74.60
	Other	0.00	0.00	0.00	0.00
	Net Sale/Income From Operations	644.45	1080.74	1268.78	5097.43
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest				
	Pharma Division	-73.21	82.45	74.97	466.66
	Real Estate Division	-38.22	-3.01	-11.68	25.57
	Other	0.00	0.00	0.00	0.00
	Total	-111.44	79.44	63.30	492.23
	Interest Income	0.00	0.00	0.00	0.00
	Interest Expenses	0.01	0.01	0.12	0.16
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00
	Profit Before Tax	-111.45	79.43	63.18	492.07
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	6573.04	12434.15	12434.16	12434.15
	Real Estate Division	6157.87	164.48	171.40	164.48
	Other	0.00	0.00	0.00	0.00
	Total (A)	12730.92	12598.64	12605.56	12598.64
	Segment Liabilities (B)				
	Pharma Division	820.30	741.50	968.40	741.50
	Real Estate Division	55.12	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00
	Total (B)	875.42	741.50	968.40	741.50
4	Total Capital Employed (Segment Assets-Segment Liabilities)				
	Pharma Division	5752.75	11692.66	11465.76	11692.66
	Real Estate Division	6102.76	164.48	171.40	164.48
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	11855.50	11857.14	11637.16	11857.14

DATE: 11.08.2023
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED




ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

NOTES:

1. The above unaudited financial results for the Quarter ended June 30, 2023 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on August 11, 2023. The above results have been reviewed by statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated financial results includes the result of Wholly Owned Subsidiary Company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this financial result.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.
7. The figures for the quarter ended 31st March 2023 are the balancing figures between the audited figures in respect of the full financial year and the year to date figures up to the third quarter which were subject to limited review.
8. The Company was reporting the profit/loss from discontinuing operation since discontinuation of manufacturing activities but from this financial year the board of directors of the Company are not expecting any revenue/expenses from discontinues division. Accordingly separate reporting is not required
9. The booking for the Company's Real estate project has been started and Company has also sold few shops, revenue of which will be reflected in next quarter.

DATE : 11.08.2023
PLACE: INDORE

For, MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321